title: Antinociceptive effect of butyl (2-phenylethynyl) selenide on formalin test in mice: Evidences for the involvement of serotonergic and adenosinergic systems.
abstract: The present study investigated the effect of per oral (p.o.) administration of butyl (2-phenylethynyl) selenide (1-50mg/kg) on formalin-induced nociception in mice. The involvement of serotonergic, adenosinergic, muscarinic cholinergic and opioid mechanisms in the antinociceptive effect was also investigated. Butyl (2-phenylethynyl) selenide inhibited both neurogenic (at doses equal or higher than 10mg/kg) and inflammatory (at doses equal or higher than 25mg/kg) phases of the nociception caused by intraplantar (i.pl.) injection of 2.5% formalin solution (20 microl), with ID(50) values of 36.7 (29.28-46.0) and 20.37 (15.74-26.36) mg/kg, respectively. This compound reduced the formalin-induced paw oedema formation (55 + or - 4%) at doses equal or higher than 25mg/kg. The antinociceptive effect of compound (25mg/kg, p.o.) was reversed by ondansetron (0.5mg/kg, a 5-HT(3) receptor antagonist) and caffeine (3mg/kg, a nonselective adenosine receptor antagonist), but not by atropine (0.1mg/kg, a non selective muscarinic antagonist), WAY100635 (0.1mg/kg, a selective 5-HT(1A) receptor antagonist), ritanserin (1mg/kg, a 5-HT(2) receptor antagonist) and naloxone (1mg/kg, a non selective opioid receptor antagonist). These results indicate that butyl (2-phenylethynyl) selenide produced antinociception in the formalin test through mechanisms that involve an interaction with serotonergic (5-HT(3)) and adenosinergic systems.
authors.affiliation: Departamento de Química, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Santa Maria, CEP 97105-900, RS, Brazil.
authors.forename: Cristiane
authors.initials: C
authors.lastname: Luchese
authors.forename: Marina
authors.initials: M
authors.lastname: Prigol
authors.forename: Carmine Inês
authors.initials: CI
authors.lastname: Acker
authors.forename: Cristina Wayne
authors.initials: CW
authors.lastname: Nogueira
mesh_terms: D000284:Administration, Oral; D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000188:drug therapy; D005557:Formaldehyde; D020128:Inhibitory Concentration 50; D008297:Male; D051379:Mice; D016566:Organoselenium Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D010146:Pain / Q000188:drug therapy*; D018047:Receptors, Purinergic P1 / Q000187:drug effects / Q000378:metabolism; D044406:Receptors, Serotonin, 5-HT3 / Q000187:drug effects* / Q000378:metabolism
chemical_list: D000700:Analgesics; D016566:Organoselenium Compounds; D018047:Receptors, Purinergic P1; D044406:Receptors, Serotonin, 5-HT3; C553905:butyl (2-phenylethynyl) selenide; D005557:Formaldehyde